CPT 0480U Metagenomic NGS Reimbursement | OpenPayer

Summary & Overview

CPT 0480U: Metagenomic NGS for Pathogen Detection in Cerebrospinal Fluid

CPT code 0480U designates a proprietary metagenomic next-generation sequencing (NGS) test developed by Mayo Clinic to identify bacteria, viruses, fungi, and parasites in cerebrospinal fluid (CSF). As a PLA code, it applies to a single, manufacturer- or laboratory-specific assay that offers broad, hypothesis-free pathogen detection, which can be critical in diagnosing complex central nervous system infections when conventional testing is inconclusive.

Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for CSF metagenomic sequencing, typical sites of service, and how the test is described in billing terms. The publication outlines benchmark considerations for utilization and reimbursement, summarizes relevant policy and coverage developments affecting laboratory PLA codes, and highlights operational factors laboratories and providers should consider when submitting and documenting CPT code 0480U.

This summary is directed at a national audience and focuses on clinical utility, billing classification, and payer coverage landscape for CPT code 0480U. Data not available in the input are noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare0480UCPTmetagenomic sequencingnext-generation sequencingcerebrospinal fluidinfectious disease diagnosticsproprietary laboratory analyseslaboratory billing

Billing Code Overview

CPT code 0480U is a Proprietary Laboratory Analyses (PLA) code for Bacteria, Viruses, Fungus, and Parasite Metagenomic Sequencing, Spinal Fluid (MSCSF) performed by Mayo Clinic. The test uses metagenomic next-generation sequencing (NGS) to detect and identify DNA and RNA from bacteria, viruses, fungi, and parasites in cerebrospinal fluid (CSF).

Service type: Metagenomic next-generation sequencing (NGS) respiratory pathogen and broad microbial detection assay applied to cerebrospinal fluid
Typical site of service: Clinical laboratory processing cerebrospinal fluid specimens; specimen collection typically occurs in inpatient or outpatient hospital settings or ambulatory clinics

Clinical & Coding Specifications

Clinical Context

A 52-year-old immunocompromised patient presents to the emergency department with fever, severe headache, photophobia, and altered mental status. Physical exam suggests meningeal irritation. A lumbar puncture is performed and cerebrospinal fluid (CSF) is sent for routine studies (cell count, glucose, protein), Gram stain and culture, and reflexively for advanced pathogen testing due to concern for atypical or undiagnosed central nervous system infection. The ordering clinician requests metagenomic next-generation sequencing (mNGS) of CSF to detect bacterial, viral, fungal, or parasitic nucleic acids when standard testing is non-diagnostic or when a broad, hypothesis-free pathogen search is clinically indicated.

The clinical workflow: after lumbar puncture, CSF is aliquoted and shipped under required conditions to the Mayo Clinic laboratory that performs the proprietary test reported with 0480U. The lab performs nucleic acid extraction, library preparation, and metagenomic sequencing of DNA and RNA, followed by bioinformatic analysis to identify pathogen sequences. Results are reported to the ordering clinician to guide targeted antimicrobial therapy, infection control decisions, or further diagnostic evaluation.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — standard billing	Use when no specific modifier applies to the service.

CPT 0330U: Bridge Women’s Health 27-Pathogen Vaginal NAAT

CPT-0421U-COLOSENSE-FECAL-MOLECULAR-COLORECTAL-CANCER-RISK-TEST

CPT 0421U: Colosense™ Fecal Molecular Colorectal Cancer Risk Test

CPT-0497U-ONCOASSURE-PROSTATE-RT-PCR-GENE-EXPRESSION-RISK-SCORE

CPT 0497U: OncoAssure Prostate RT‑PCR Gene Expression Risk Score

CPT-0341U-SINGLE-CELL-PRENATAL-DIAGNOSIS-SCPD-TEST

CPT 0341U: Single Cell Prenatal Diagnosis (SCPD) Test

CPT-0581U-NON-HLA-AUTOANTIBODY-PANEL-MAYO-CLINIC

CPT 0581U: Autoantibody to Non–HLA Panel (Mayo Clinic Jacksonville)

CPT-0242U-GUARDANT360-CDX-NGS-CTDNA-TUMOR-PROFILING

CPT 0242U: Guardant360 CDx NGS ctDNA Tumor Profiling

CPT-0268U-VERSITI-AHUS-GENETIC-EVALUATION-NGS-15-GENES

CPT 0268U: Versiti aHUS Genetic Evaluation, 15-Gene NGS Panel

CPT-0616U-TRUD-MDS-ALZHEIMERS-MCI-METHYLATION-ASSAY

CPT 0616U: TruD MDS Alzheimer's & MCI Methylation Risk Assay

CPT-0499U-OPTISEQ-DUAL-CANCER-PANEL-NGS-FFPE

CPT 0499U: OptiSeq Dual Cancer Panel NGS for FFPE Tumor Tissue

CPT-0142U-EPLEX-BCID-GRAM-NEGATIVE-PANEL-MOLECULAR-BLOOD-CULTURE

CPT 0142U: ePlex BCID Gram–Negative Panel for Positive Blood Cultures

Showing 1–10 of 536

Taxonomy Code	Specialty	Notes
`208000000X`	Pathology	Laboratory directors and clinical pathologists who oversee testing and interpretation.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`A87.9`	Viral meningitis, unspecified	Viral meningitis is a common indication for CSF metagenomic testing when routine viral PCR panels are negative.

| G00.9 | Bacterial meningitis, unspecified | When standard CSF culture and Gram stain are insufficient, mNGS can identify atypical bacterial pathogens.

| B99 | Other and unspecified infectious diseases | Use for infections of uncertain etiology where broad pathogen detection is required.

| G03.9 | Meningitis, unspecified | Non-specific meningitis diagnosis prompting broad-range CSF pathogen testing.

| A17.9 | Tuberculosis of nervous system, unspecified | CNS tuberculosis can be difficult to detect by conventional methods; mNGS may identify Mycobacterium sequences.

| B58.9 | Toxoplasmosis, unspecified | Parasitic CNS infections such as Toxoplasma can be detected by nucleic acid-based metagenomic methods.

| B44.9 | Aspergillosis, unspecified | Fungal CNS infections may be detected by CSF mNGS when culture and antigen testing are negative.

| R41.82 | Altered mental status, unspecified | Symptom code associated with presentations that trigger CSF evaluation and advanced pathogen testing.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`62270`	Spinal puncture, therapeutic or diagnostic (lumbar puncture)	Performed before `0480U` to obtain CSF specimen for metagenomic sequencing.

| 87798 | Infectious agent detection by nucleic acid (e.g., PCR), multiple organisms, multiplex; unlisted multiplex nucleic acid-based tests | May be used for other molecular CSF pathogen panels; often ordered in parallel or prior to mNGS.

| 88305 | Level IV surgical pathology, gross and microscopic examination | Used if tissue or cytology from CNS is submitted in conjunction with CSF testing for comprehensive diagnostic evaluation.

| 80502 | Infectious agent antibody detection, single step method (e.g., rapid), each agent | Serologic tests that may accompany CSF mNGS to evaluate systemic immune response to suspected pathogens.

| 0001U | Metagenomic sequencing or other proprietary PLA codes (example of PLA usage) | Illustrates the class of Proprietary Laboratory Analyses (PLA) codes to which 0480U belongs; other PLA codes may be billed for different vendor-specific tests performed in the diagnostic pathway.

OpenPayer